Glenmark Pharmaceuticals Inc, USA, the wholly owned subsidiary of Mumbai-based Glenmark Pharmaceuticals has acquired two FDA approved products from Clonmel Healthcare Ltd - a Republic of Ireland corporation.

The acquisition includes the complete regulatory filing assets of two products, which were most recently marketed by ESI Lederle. The market-size for the products in the US is approximately $50 million and has limited generic competition, an official release from Glenmark said.

Jeffrey Weiss, CEO of Glenmark Pharmaceutical Inc. said, "The acquisition accelerates our product growth plan in the US. It also advances the introduction and launch of our commercial front end and the Glenmark label in the US marketplace".

Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals Ltd said: "The current acquisition, we believe, will help advance the USFDA inspection of our new formulations plant at Goa. It will also further our ability to launch and deliver products in the regulated markets under the Glenmark label".

Glenmark's US subsidiary has also recently filed its first complete Para 3 ANDA under its own label. The product has a generic market size of approximately USD 200 Million in the US.

Glenmark plans to launch the products in the next financial year. The company expects to capture approximately 25 per cent market share for each product within one year from launch. It is looking at filing a total of 8-10 ANDA's on its own label in the current financial year. In addition to its own product filings, Glenmark also has a tie-up with KV Pharmaceuticals, a leading US specialty company, for the development and marketing of 8 additional ANDAs. Under this agreement, the products will be developed by Glenmark and filed and commercialized by KV under a joint label, the release added.

Clonmel Healthcare Ltd is a subsidiary of Stada, a German Pharmaceutical major.